Severity of SARS-CoV-2 Omicron variant infection in heart transplant recipients.
SARS-CoV-2 Omicron variant
antibody evasion
heart transplant recipients
mortality
vaccine-induced antibody response
Journal
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
31
08
2022
revised:
10
01
2023
accepted:
26
01
2023
medline:
24
4
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
SARS-CoV-2 Omicron variant was first detected in France mid-November 2021 in wastewater treatment plants while cases started to increase at the beginning of December. The maximum incidence occurred in mid-January 2022. The Omicron wave spread rapidly throughout France in general population with lower case-fatality rate compared with previous waves. Little is known about infection with Omicron variant in heart transplant (HT) recipients. In this study, we examined incidence and mortality rate of COVID-19 in the general population and among 1,263 HT recipients during the period from June, 2021 to February, 2022, described characteristics of HT recipients infected with SARS-CoV-2 during Omicron (December 1st, 2021-February 7, 2022) and Delta (June 1st- November 30, 2021) periods, and compared hospital course of HT recipients with Omicron and Delta variant infection. Our findings contrast with the reported lower severity for Omicron variant infection compared with Delta variant infection in immunocompetent individuals.
Identifiants
pubmed: 36822931
pii: S1053-2498(23)00031-1
doi: 10.1016/j.healun.2023.01.012
pmc: PMC9890932
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
558-561Informations de copyright
Copyright © 2023 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure statement The authors have no disclosure regarding the present study.
Références
Euro Surveill. 2022 Jan;27(4):
pubmed: 35086614
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Clin Med Insights Circ Respir Pulm Med. 2022 Jun 5;16:11795484221105327
pubmed: 35693423
Eur J Prev Cardiol. 2022 May 6;29(6):e224-e226
pubmed: 34757386
Emerg Infect Dis. 2022 Jul;28(7):1355-1365
pubmed: 35642476
Cells. 2022 Mar 02;11(5):
pubmed: 35269476
J Heart Lung Transplant. 2022 Oct;41(10):1417-1425
pubmed: 35710484
Lancet. 2022 Apr 2;399(10332):1303-1312
pubmed: 35305296
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198